DTIL
$6.93
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
Intraday
Recent News
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of +271.43% and +178.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences: Q4 Earnings Snapshot
The Durham, North Carolina-based company said it had profit of $1.05 per share. Earnings, adjusted for one-time gains and costs, were 36 cents per share. The genome editing company posted revenue of $34.2 million in the period.
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio
In early March 2026, Precision BioSciences announced it hit a clinical milestone under its license with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a US$7.5 million payment that combines US$5.25 million in cash and a US$2.25 million equity purchase, while TG separately reported strong 2025 revenue and earnings growth. The azer-cel milestone adds an emerging autoimmune cell therapy program alongside BRIUMVI, signalling that TG Therapeutics is...
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story
TG Therapeutics and Precision BioSciences reached a clinical milestone for azercabtagene zapreleucel in progressive multiple sclerosis. The milestone advances their autoimmune collaboration beyond BRIUMVI into broader cell therapy programs. The progress in azer cel adds another clinical asset to TG Therapeutics' pipeline in autoimmune disease. TG Therapeutics, traded as NasdaqCM:TGTX, now has fresh clinical traction alongside BRIUMVI as it pushes deeper into autoimmune programs. The stock...